<DOC>
	<DOCNO>NCT00804375</DOCNO>
	<brief_summary>Primary : To compare analgesic effect 12 week topical 2PX stump pain . Secondary : To prospectively measure efficacy safety variable topical 2PX stump pain . Exploratory analysis perform measure efficacy safety variable topical 2PX phantom pain</brief_summary>
	<brief_title>Study Efficacy , Safety Tolerability Topical 2PX ( Strontium Chloride Hexahydrate ) Patients With Chronic , Moderate-to-severe Lower Limb Post-amputation Stump Pain</brief_title>
	<detailed_description />
	<criteria>Lower limb amputation least 6 month prior Visit 1 . Amputation must transtibial , transfemoral knee . For patient transfemoral amputation , point amputation must ≥10 cm inguinal region . Presenting moderatetosevere stump pain . For purpose study , follow criterion must apply : 1 . Stump pain commence post amputation continue Visit 1 despite continue use analgesic medication 2 . Stump pain present daily basis 3 . Stump pain intensity Average stump Pain Intensity ( AsPI ) ≥40 100 mm VAS Screening 4 . Stump pain intensity randomisation visit : Mean ( 7 day runin period ) AsPI rating ≥40 100 mm VAS . 5 . Pain site extremity amputation . The pain locate mainly stump . ( Patients concurrent phantom pain may enrol study . ) 6 . Stump pain persist despite proper heal stump Outpatients , age 18 year Underlying therapy ( e.g. , rehabilitation procedure , analgesia , physiotherapy , spinal cord stimulation ( except topical subcutaneous local analgesic ) ) may continue throughout duration study , regimen stable 4 week immediately prior Visit 1 . If underlying therapy continue study regimen must maintain duration study . Written informed consent Patients forefoot amputation alone exclude participation . Patients receive treatment topical subcutaneously administer analgesic agent stump phantom pain 4 week prior study entry ( i.e . Visit 1 ) . Underlying therapy ( e.g. , rehabilitation procedure , analgesia , physiotherapy , spinal cord stimulation ) permit regimen stable 4 week immediately prior Visit 1 . After 7 day runin phase : patient take new change dose underlying analgesic medication ( except rescue medication define protocol ) . Patients open wound , burn nonintact skin site ( ) study drug administration ( unhealed stump ) . Patients significant discomfort prosthesis limit use prosthesis . Use prosthesis requirement participation study . Pregnancy Female patient childbearing potential unwilling use adequate contraception measure throughout duration study . For purpose study , adequate contraception define : oral , injected implant hormonal method contraception ; OR placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; OR barrier method contraception : Condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Note : Male sterilization abstinence acceptable method birth control would preclude enrolment study . Note : For postmenopausal woman : le 12 month since last spontaneous menstrual bleeding exclude patient unless willing utilise acceptable method contraception duration study . Breastfeeding/lactating mother Any active malignant disease ( except basal cell carcinoma ; BCC ) Patients previously receive 2PX . Patients require concomitant administration strontium ranelate ( Protelos® ) Patients receive investigational drug use investigational device within 30 day prior study entry . Patients unable comply study assessment Patients document suspected current alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stump pain</keyword>
</DOC>